定增热度再起！葛兰、赵蓓、朱少醒……集体出手

Core Viewpoint - The recent surge in the private placement market has attracted significant attention, particularly with prominent fund managers participating in the Baili Tianheng private placement, indicating a strong interest in seeking excess returns outside the secondary market [1][2]. Group 1: Participation of Fund Managers - Notable fund managers such as Ge Lan, Zhao Bei, and Zhu Shao Xing have products involved in the Baili Tianheng private placement, highlighting the recognition of the target company's growth potential [2][3]. - The participation of these well-known fund managers reflects their active pursuit of structural opportunities in the market, even amidst fluctuations in the pharmaceutical sector [4][6]. Group 2: Details of Baili Tianheng Private Placement - Baili Tianheng, a company focused on cutting-edge biopharmaceuticals, completed its private placement on September 19, raising a total of 3.764 billion yuan at an issue price of 317 yuan per share [3]. - The funds allocated by the participating funds include approximately 588 million yuan from Zhongou Medical Health for 1.8559 million shares and about 90.51 million yuan from Zhongou Medical Innovation for 285,500 shares [3]. Group 3: Market Trends and Future Outlook - The private placement market is experiencing heightened activity, with various fund managers actively engaging in different projects, contributing positively to fund net value growth [5][6]. - Analysts note a shift towards high-quality development in the merger and acquisition market, driven by policy support and innovative market practices, which may enhance the overall supply of private placements in the coming years [6][7].